Skip to content

Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)

Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01088217
Acronym
GWAS
Enrollment
8000
Registered
2010-03-17
Start date
2008-07-31
Completion date
2025-06-30
Last updated
2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Familial Interstitial Pneumonia, Familial Pulmonary Fibrosis, Idiopathic Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis

Keywords

Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis, Idiopathic Interstitial Pneumonia, Familial Interstitial Pneumonia, Pulmonary Fibrosis

Brief summary

The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis. Finding the genes that cause pulmonary fibrosis is the first step at developing better methods for early diagnosis and improved treatment for pulmonary fibrosis. The overall hypothesis is that inherited genetic factors predispose individuals to develop pulmonary fibrosis.

Detailed description

Familial Pulmonary Fibrosis (FPF) is a sub-category of the idiopathic interstitial pneumonias (IIPs). IIPs are progressive lung conditions, with limited treatment options and unknown etiology. Though the IIPs have been associated with both genetic risk factors and environmental exposures, the molecular mechanism underlying disease progression remain poorly understood. This investigation seeks to identify a group of genetic loci that play a role in the development of familial interstitial pneumonia (FIP) or FPF, where 2 or more cases of IIP are seen within a family.

Interventions

None listed

Sponsors

University of Colorado, Denver
CollaboratorOTHER
Vanderbilt University
CollaboratorOTHER
Landspitali University Hospital
CollaboratorOTHER
National Jewish Health
Lead SponsorOTHER

Study design

Observational model
FAMILY_BASED
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Two or more family members with a clinical diagnosis of Idiopathic Pulmonary Fibrosis (IPF) or Idiopathic Interstitial Pneumonia (IIP) * Additional family members may be eligible to participate if two family members are suspected of or diagnosed as having Idiopathic Pulmonary Fibrosis (IPF) or Idiopathic Interstitial Pneumonia (IIP)

Exclusion criteria

* Individuals whose pulmonary fibrosis is due to a known cause rather than idiopathic * Individuals whose pulmonary fibrosis is due to a broader genetic syndrome

Design outcomes

Primary

MeasureTime frameDescription
Identify a group of genetic loci that play a role in the development of familial interstitial pneumonia and idiopathic interstitial pneumonia.10 yearsThe purpose of this study is to investigate inherited genetic factors that play a role in the development of pulmonary fibrosis and to identify a group of genetic loci/genes that predispose individuals to develop IIP. We will achieve this goal by employing various methods of genetic technology for gene discovery.

Secondary

MeasureTime frameDescription
Develop biomarkers using proteomic and genomic approaches that will facilitate establishing the diagnosis and prognosis of both familial and sporadic forms of idiopathic interstitial pneumonia (IIP).10 yearsA peripheral blood biomarker or biological signature (gene or protein expression pattern) of idiopathic interstitial pneumonias (IIPs) will simplify and improve the accuracy of diagnosis of IIP and diagnose individuals at an earlier, more treatable, stage of their disease. A peripheral blood biomarker for the diagnosis of IIPs and other interstitial lung diseases (ILDs) will potentially decrease the need for invasive surgical lung biopsy, and thereby avoid the additional cost, morbidity, and mortality associated with surgical lung biopsy.

Countries

Iceland, United States

Contacts

Primary ContactJulie Powers, MHS
julia.powers@ucdenver.edu303-724-6539
Backup ContactJanet Talbert, MS, CGC
talbertj@njhealth.org1-800-423-8891

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026